Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma

被引：0
|
作者：
Franck Morschhauser
Martin J. S. Dyer
Harriet S. Walter
Alexey V. Danilov
Loic Ysebaert
Daniel James Hodson
Christopher Fegan
Simon A. Rule
John Radford
Guillaume Cartron
Krimo Bouabdallah
Andrew John Davies
Stephen Spurgeon
Nishanthan Rajakumaraswamy
Biao Li
Rita Humeniuk
Xi Huang
Pankaj Bhargava
Juliane M. Jürgensmeier
Gilles Salles
机构：
[1] GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées,Univ. Lille, CHU Lille, ULR 7365
[2] University of Leicester,Ernest and Helen Scott Haematological Research Institute
[3] City of Hope National Medical Center,WT
[4] Département d’Hématologie IUCT-Oncopole,MRC Stem Cell Institute
[5] University of Cambridge,Department of Clinical Hematology
[6] University Hospital of Wales,Hematology Clinic
[7] University of Plymouth Medical School,Cancer Research UK Centre
[8] University of Manchester and The Christie NHS Foundation Trust,Knight Cancer Institute
[9] University Hospital of Montpellier and UMR-CNRS 5535,Hospices Civils de Lyon, Department of Hematology
[10] University Hospital of Bordeaux,undefined
[11] University of Southampton,undefined
[12] Oregon Health and Science University,undefined
[13] Gilead Sciences,undefined
[14] Inc,undefined
[15] Université de Lyon,undefined
来源：
Leukemia | 2021年 / 35卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2108 / 2113
页数：5
相关论文
共 50 条
  • [1] Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
    Morschhauser, Franck
    Dyer, Martin J. S.
    Walter, Harriet S.
    Danilov, Alexey V.
    Ysebaert, Loic
    Hodson, Daniel James
    Fegan, Christopher
    Rule, Simon A.
    Radford, John
    Cartron, Guillaume
    Bouabdallah, Krimo
    Davies, Andrew John
    Spurgeon, Stephen
    Rajakumaraswamy, Nishanthan
    Li, Biao
    Humeniuk, Rita
    Huang, Xi
    Bhargava, Pankaj
    Jurgensmeier, Juliane M.
    Salles, Gilles
    LEUKEMIA, 2021, 35 (07) : 2108 - 2113
  • [2] Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
    Danilov, Alexey V.
    Herbaux, Charles
    Walter, Harriet S.
    Hillmen, Peter
    Rule, Simon A.
    Kio, Ebenezer A.
    Karlin, Lionel
    Dyer, Martin J. S.
    Mitra, Siddhartha S.
    Yi, Ping Cheng
    Humeniuk, Rita
    Huang, Xi
    Zhou, Ziqian
    Bhargava, Pankaj
    Jurgensmeier, Juliane M.
    Fegan, Christopher D.
    CLINICAL CANCER RESEARCH, 2020, 26 (12) : 2810 - 2818
  • [3] Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia
    Danilov, Alexey V.
    Herbaux, Charles
    Dyer, Martin J. S.
    Hillmen, Peter
    Rule, Simon
    Kio, Ebenezer A.
    Huang, Xi
    Mitra, Siddhartha
    Karlin, Lionel
    Fegan, Christopher
    BLOOD, 2018, 132
  • [4] Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies
    Salles, Gilles A.
    Morschhauser, Franck
    Cheson, Bruce
    Rule, Simon A.
    Fegan, Christopher
    Guillaume, Cartron
    Nelson, Cara
    Yang, Yingsi
    Mitra, Siddhartha
    Starodub, Alexander
    Dyer, Martin J. S.
    BLOOD, 2016, 128 (22)
  • [5] Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
    Tilly, H.
    Morschhauser, F.
    Salles, G.
    Casasnovas, R-O
    Feugier, P.
    Molina, T. J.
    Jardin, F.
    Terriou, L.
    Haioun, C.
    Coiffier, B.
    LEUKEMIA, 2013, 27 (01) : 252 - 255
  • [6] Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
    H Tilly
    F Morschhauser
    G Salles
    R-O Casasnovas
    P Feugier
    T J Molina
    F Jardin
    L Terriou
    C Haioun
    B Coiffier
    Leukemia, 2013, 27 : 252 - 255
  • [7] Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b Study
    Palomba, M. Lia
    Till, Brian G.
    Park, Steven I.
    Morschhauser, Franck
    Cartron, Guillaume
    Marks, Reinhard
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Popplewell, Leslie L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : E443 - E451
  • [8] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
    Awan, Farrukh T.
    Thirman, Michael J.
    Patel-Donnelly, Dipti
    Assouline, Sarit
    Rao, Arati, V
    Ye, Wei
    Hill, Brian
    Sharman, Jeff P.
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
  • [9] Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study
    Wang, Yucai
    Laplant, Betsy
    King, Rebecca L.
    Micallef, Ivana N.
    Ansell, Stephen M.
    Tun, Han W.
    Iqbal, Madiha
    Thanarajasingam, Gita
    Rosenthal, Allison C.
    Inwards, David J.
    Johnston, Patrick B.
    Porrata, Luis F.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Nowakowski, Grzegorz S.
    BLOOD, 2021, 138
  • [10] Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group
    Martin, Alejandro
    Redondo, Alba M.
    Dlouhy, Ivan
    Salar, Antonio
    Gonzalez-Barca, Eva
    Canales, Miguel
    Montes-Moreno, Santiago
    Ocio, Enrique M.
    Lopez-Guillermo, Armando
    Caballero, Dolores
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 245 - 252
12345